Investment
Features
FeesSafety
Academy
More
Pluang+

Compare FedEx Corporation (FDX) vs Tilray Brands Inc (TLRY) Price & Performance

FedEx CorporationTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

FedEx Corporation vs Tilray Brands Inc — how do they compare? FedEx Corporation trades at $290.69 (market cap $69.04B), while Tilray Brands Inc trades at $3.48 (market cap $530.54M). The key difference: FedEx Corporation is far larger — about 130.1× Tilray Brands Inc's market cap, and FedEx Corporation pays a 1.67% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Tilray Brands Inc for 31 Days on average.

FDXTLRY
Market Cap
$69.04B$530.54M
Volume
1,287,3679,099,075
Sector
IndustrialsHealth
52-Week High
$339.35$21.00
52-Week Low
$180.87$3.57
Typical Hold Time
87 Days31 Days
Enterprise Value
$98.68B$684.46M
Dividend Yield
1.67%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

FedEx Corporation

FedEx (FDX) trades at $289.04, showing minimal daily change. The stock exhibits a bearish technical signal with key support at $288 and resistance at $290. Fundamentally, the company maintains stable profitability with a net income margin of 4.68% and a P/E ratio of 15.73, while recent earnings beats in Q4 2025 and Q1 2026 highlight operational strength. Positive developments include a $300 million electric truck order and shareholder approval of executive compensation, though rising fuel prices present a near-term headwind.

The outlook for FDX is cautiously optimistic, supported by analyst consensus favoring a buy rating with a $307.55 price target. Investment appeal lies in its reasonable valuation and dividend yield, but risks include margin pressure from fuel costs, competitive intensity, and macroeconomic sensitivity. The stock's trajectory will likely hinge on execution of cost initiatives and freight demand trends.

Tilray Brands Inc

TLRY trades at $3.465, down 6.73% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows weak technical momentum with oversold RSI readings but faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins, and declining revenue growth. Recent news highlights the company's struggles with profitability despite record annual revenue, with shares down over 50% year-to-date as investors question the cannabis company's path to sustainable growth.

TLRY presents a high-risk opportunity with significant downside protection from its low P/B ratio of 0.33, but requires substantial operational improvement to justify investment. The bullish case hinges on potential marijuana reform catalysts and BrewDog integration progress, while risks include ongoing losses, competitive pressures, and execution challenges in a volatile regulatory environment.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FDX
100% Buy0% Sell
Avg holding period · 87 Days
TLRY
100% Buy0% Sell
Avg holding period · 31 Days

Top news

Latest headlines on both assets

About FedEx Corporation

FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.

Read more on FDX →

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY →